Immix Biopharma Inc

IMMX13 Dec 2024
Healthcare
$2.29
-0.08 (-8.19%)
Lowest Today
$2.12
Highest Today
$2.4
Today’s Open
$2.29
Prev. Close
$2.32
52 Week High
$7.75
52 Week Low
$1.26
To Invest in Immix Biopharma Inc

Immix Biopharma Inc

Healthcare
IMMX13 Dec 2024
-0.08 (-8.19%)
1M
3M
6M
1Y
5Y
Low
$2.12
Day’s Range
High
$2.4
2.12
52 Week Low
$1.26
52-Week Range
52 Week High
$7.75
1.26
1 Day
-
1 Week
-14.23%
1 month return
+33.33%
3 month return
+18.91%
6 month return
+7.84%
1 Year return
-46.34%
3 Years return
-40.21%
5 Years return
-
10 Years return
-
Institutional Holdings
AIGH Capital Management, LLC
4.08
Bleichroeder LP
3.09
Cable Car Capital LLC
2.89
Vanguard Group Inc
2.54
Vanguard Total Stock Mkt Idx Inv
1.82
Vanguard Institutional Extnd Mkt Idx Tr
0.72
Geode Capital Management, LLC
0.55

Market Status

Fundamentals
Market Cap
63.82 mln
PB Ratio
3.64
PE Ratio
0
Enterprise Value
45.22 mln
Total Assets
19.93 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Organisation
Immix Biopharma Inc
Employees
14
Industry
Biotechnology
CEO
Dr. Ilya  Rachman M.B.A., M.D., MBA, Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step